Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Centene ($CNC) announced that it will launch its health insurance marketplace product in Missouri in 2018. The company intends to distribute its Ambetter product in 40 counties. 25 of these counties were not expected to have any other insurers available for enrollment. The company is carrying out this program through its Celtic Insurance Co. These counties were left without any insurer after the departure of BlueCross BlueShield of Kansas City. The company stock has shown strong growth as it gained over 41 percent this year so far. Its 52 weeks low and high stand at $50 and $85.79 respectively. Centene has market cap of $13.75 billion.

Skyline Medical ($SKLN) stock soared as the company provided shareholder update. The company noted that it recently received the permission to affix the CE mark to the Streamway system. This approval will allow the company to market and sell the Streamway in 32 European countries. The company is currently in the process of identifying potential markets and setting up the distribution system. It expects to complete the process of rolling out the product in the European markets by early 2018.
The company stock gained over 12 percent in its Friday trading session, trimming its Year to Date losses to 47 percent. The company stock has lost over 60 percent of its value in the past 12 months.

 

BioMarin Pharmaceutical ($BMRN) announced submitting a Biologics License Application to the FDA for pegvaliase, a Phenylketonuria treatment. The company also intends to submit an application for registration in the European Union by the end of the year.

Astellas Pharma ($ALPMF) announced submitting a supplemental New Drug Application to the FDA seeking approval for using mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. The application is supported by the data from the global Phase 3 SYNERGY I, SYNERGY II and BESIDE studies.

 

GlaxoSmithKline ($GSK) announced a collaboration with Exscientia. The pharma company will provide $43 million in research funding to Exscientia for improving drug discovery efficiency. The deal covers up to 10 disease targets with money dispersed in preclinical milestone payments.
  
MannKind ($MNKD) announced filing to offer 7.3 million shares of series A warrants and 2.4M shares of series B warrants. The company intends to raise $72.75 million in the offering through the issuance of the warrants at $7.50 per share.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Canaccord Genuity
Reiterates
Aerie Pharmaceuticals (AERI)
Buy

Low
Berenberg Bank
Downgrades
Bayer AG (BAYRY)
Buy -> Hold

Low
J P Morgan Chase & Co
Reiterates
Nevro Corp. (NVRO)
Overweight
$102.00
N/A

Gainers (% price change)Last TradeChangeMkt CapCARDIOME PHARMA CORPCRME4.52+0.33 (7.88%)140.45MAmarin Corp. plc (ADR)AMRN4.03+0.17 (4.40%)1.12BBioScrip IncBIOS2.71+0.11 (4.02%)286.72MCodexis, Inc.CDXS5.45+0.20 (3.81%)265.05MAVEO Pharmaceuticals, IncAVEO2.22+0.08 (3.74%)230.97MLosers (% price change)CyberOptics CorporationCYBE20.65-0.95 (-4.40%)135.83MPacific Biosciences ofPACB3.56-0.16 (-4.30%)395.34MPDL BioPharma IncPDLI2.47-0.11 (-4.26%)396.10MRegeneron PharmaceuticalsREGN491.14-18.79 (-3.68%)51.87BBioCryst PharmaceuticalsBCRX5.56-0.21 (-3.64%)443.30MMost Actives (dollar volume)Johnson & JohnsonJNJ132.29-0.35 (-0.26%)353.22BRegeneron PharmaceuticalsREGN491.14-18.79 (-3.68%)51.87BMerck & Co., Inc.MRK64.09-0.25 (-0.39%)173.09BCelgene CorporationCELG129.87-1.83 (-1.39%)99.49BGilead Sciences, Inc.GILD70.78-0.08 (-0.11%)91.13B